Daphne Koller, founder and CEO of Insitro, one of the first-generation companies using AI to speed up and improve drug discovery, offers a reality check on what AI can and cannot yet do for the discovery of new medicines, after years of collecting and curating biological data to approach the most important hurdle in R&D, human clinical trials. She details programmes for fatty liver disease, ALS and brown-fat-driven markers with implications for cardiometabolic disease.
Published Nov 3, 2026 · 1 h 4 min